Furthermore, longitudinal analyses of PD incidents in Norway demonstrated that the use of salbutamol is associated with a decreased risk of developing PD while treatment with β-AR antagonist (beta-blocker) propranolol increased the risk of suffering from PD (Mittal et al., 2017). The gene discussed is ADRB2; the disease is Parkinson disease.